HUTCHMED (China) Limited
HCM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | -24.8% | 96.5% | 19.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 44.6% | 54.1% | 27% | 27.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -6.9% | 2.2% | -96.1% | -96.7% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $0 | $0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 6% | 12% | -84.6% | -54.7% |
| EPS | 0.22 | 0.6 | -2.15 | -1.25 |
| % Growth | -63.3% | 127.9% | -72% | – |
| EPS Diluted | 0.22 | 0.6 | -2.15 | -1.25 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 2.2% | 8% | -94.1% | -58.4% |